1-4 of 4
Jeff Porte Sharman, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia

Chris L. Pashos, PhD, Christopher R Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Charles M Farber, MD, PhD, Thomas J. Kipps, M.D., Ph.D, Susan Lerner, MS, BA, Neil Kay, MD, Jeff Porte Sharman, MD, David L. Grinblatt, MD, Ian W. Flinn, MD, PhD, Mark Kozloff, MD, Arlene S Swern, PhD, Zeba M. Kahn, Ph.D, Thomas K. Street, RPh, Gale Harding, MA, Kristen A Sullivan, MBA, Michael J Keating, MD
Journal: Blood
Blood (2011) 118 (21): 4591.
https://doi.org/10.1182/blood.V118.21.4591.4591
Published: 2011
Journal Articles

Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

Chris L. Pashos, PhD, Christopher R Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Charles M Farber, MD, PhD, Thomas J. Kipps, M.D., Ph.D, Susan Lerner, MS, BA, Neil Kay, MD, Jeff Porte Sharman, MD, David L. Grinblatt, MD, Ian W. Flinn, MD, PhD, Mark Kozloff, MD, Arlene S Swern, PhD, Zeba M. Kahn, Ph.D, Thomas K. Street, RPh, Kristen A Sullivan, MBA, Gale Harding, MA, Michael J Keating, MD
Journal: Blood
Blood (2011) 118 (21): 2085.
https://doi.org/10.1182/blood.V118.21.2085.2085
Published: 2011
Journal Articles

The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies

Jan A. Burger, MD, PhD, Susan O'Brien, Nathan Fowler, MD, Ranjana Advani, MD, Jeff Porte Sharman, MD, Richard R. Furman, MD, Raquel Izumi, PhD, Joseph Buggy, PhD, David Loury, PhD, Ahmed Hamdy, MD, John C. Byrd, MD, Kristie A. Blum, MD
Journal: Blood
Blood (2010) 116 (21): 57.
https://doi.org/10.1182/blood.V116.21.57.57
Published: 2010
Journal Articles

The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study

Nathan Fowler, MD, Jeff Porte Sharman, MD, Sonali M Smith, MD, Thomas Boyd, MD, Barbara Grant, MD, Kathryn S. Kolibaba, MD, Richard R. Furman, MD, Joseph Buggy, David Loury, PhD, Ahmed Hamdy, Ranjana Advani, MD
Journal: Blood
Blood (2010) 116 (21): 964.
https://doi.org/10.1182/blood.V116.21.964.964
Published: 2010